Ne{open}-(carboxymethyl)lysine linkage to α-synuclein and involvement of advanced glycation end products in α-synuclein deposits in an MPTP-intoxicated mouse model

Biochimie

Volumn 92, Issue 10, 2010, Pages 1379-1386

  Choi, Yeong Gon ^a   Lim, Sabina ^a  

^a Kyung Hee University   (South Korea)

Author keywords

CEL; CML; Parkinson's disease; Pentosidine; Pyrraline

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADVANCED GLYCATION END PRODUCT; ALPHA SYNUCLEIN; CD11B ANTIGEN; DOPAMINE TRANSPORTER; N EPSILON (CARBOXYMETHYL)LYSINE; PENTOSIDINE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NONHUMAN; OLIGOMERIZATION; PARKINSONISM; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; INTOXICATION; METABOLISM; PARKINSON DISEASE; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; LYSINE; MICE; MICE, INBRED C57BL; MPTP POISONING; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 77957109627     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.06.025     Document Type: Article

References (47)

1. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J. 2007, 48:339-355.
2. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 2001, 108:1263-1282.
3. Monte Di D.A. Mitochondrial DNA and Parkinson's disease. Neurology 1991, 41:38-42.
4. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 1985, 36:2503-2508.
5. Carboni S., Melis F., Pani L., Hadjiconstantinou M., Rossett Z.L. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP). Neurosci. Lett. 1990, 117:129-133.
6. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262:689-695.
7. Shults C.W. Lewy bodies. Proc. Natl. Acad. Sci. USA 2006, 103:1661-1668.
8. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988, 318:1315-1321.
9. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992, 15:1835-1843.
10. Ulrich P., Cerami A. Protein glycation, diabetes, and aging. Recent Prog. Horm. Res. 2001, 56:1-21.
11. Cerami A., Vlassara H., Brownlee M. Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism 1985, 34:37-42.
12. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91:4766-4770.
13. Castellani R., Smith M.A., Richey P.L., Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996, 737:195-200.
14. Dei R., Takeda A., Niwa H., Li M., Nakagomi Y., Watanabe M., Inagaki T., Washimi Y., Yasuda Y., Horie K., Miyata T., Sobue G. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol. 2002, 104:113-122.
15. Münch G., Lüth H.J., Wong A., Arendt T., Hirsch E., Ravid R., Riederer P. Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation?. J. Chem. Neuroanat. 2000, 20:253-257.
16. Castellani R.J., Perry G., Siedlak S.L., Nunomura A., Shimohama S., Zhang J., Montine T., Sayre L.M., Smith M.A. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett. 2002, 319:25-28.
17. Shaikh S., Nicholson L.F. Advanced glycation end products induce in vitro cross-linking of α -synuclein and accelerate the process of intracellular inclusion body formation. J. Neurosci. Res. 2008, 86:2071-2082.
18. Lee D., Park C.W., Paik S.R., Choi K.Y. The modification of α-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim. Biophys. Acta 2009, 1794:421-430.
19. Chen L., Wei Y., Wang X., He R. Ribosylation rapidly induces α -synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 2010, 5:e9052.
20. e{open}-(carboxyethyl)-lysine (CEL): immunochemical quantification of CML with a specific antibody. J. Biochem. 2004, 136:831-837.
21. Ling X., Nagai R., Sakashita N., Takeya M., Horiuchi S., Takahashi K. Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats and in rats with streptozotocin-induced diabetes. Lab. Invest. 2001, 81:845-861.
22. Nagai R., Horiuchi S., Unno Y. Application of monoclonal antibody libraries for the measurement of glycation adducts. Biochem. Soc. Trans. 2003, 31:1438-1440.
23. Choi Y.G., Lim S. Characterization of anti-advanced glycation end products antibodies to nonenzymatically lysine-derived and arginine-derived glycated products. J. Immunoassay Immunochem. 2009, 30:386-399.
24. Kato S., Itoh K., Ochiai M., Iwai A., Park Y., Hata S., Takeuchi K., Ito M., Imaki J., Miura S., Yakabi K., Kobayashi M. Increased pentosidine, an advanced glycation end-product, in urine and tissue reflects disease activity in inflammatory bowel diseases. J. Gastroenterol. Hepatol. 2008, 23:S140-S145.
25. e{open}-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain. Pathol. Int. 2002, 52:563-571.
26. Bezard E., Dovero S., Bioulac B., Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp. Neurol. 1997, 148:288-292.
27. Bezard E., Dovero S., Bioulac B., Gross C. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci. Lett. 1997, 234:47-50.
28. Jung B.D., Shin E.J., Nguyen X.K., Jin C.H., Bach J.H., Park S.J., Nah S.Y., Wie M.B., Bing G., Kim H.C. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem. Int. 2010, 56:229-244.
29. Lee Y.B., Nagai A., Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 2002, 69:94-103.
30. Pardridge W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2005, 2:129-138.
31. Choi Y.G., Park J.H., Lim S. Acupuncture inhibits ferric iron deposition and ferritin-heavy chain reduction in an MPTP-induced parkinsonism model. Neurosci. Lett. 2009, 450:92-96.
32. Knyihár-Csillik E., Csillik B., Pákáski M., Krisztin-Péva B., Dobó E., Okuno E., Vécsei L. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience 2004, 126:899-914.
33. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
34. Jakus V., Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. 2004, 53:131-142.
35. Monnier V.M. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 2003, 419:1-15.
36. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., Citron M. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 1999, 274:9843-9846.
37. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., Masliah E. α-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157:401-410.
38. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 2000, 74:721-729.
39. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
40. Fornai F., Schlüter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Südhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA 2005, 102:3413-3418.
41. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison R.C., Lau Y.S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 2002, 956:156-165.
42. Alvarez-Fischer D., Guerreiro S., Hunot S., Saurini F., Marien M., Sokoloff P., Hirsch E.C., Hartmann A., Michel P.P. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J. Neurochem. 2008, 107:701-711.
43. Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., Founds H., Atwood C.S., Perry G., Smith M.A. Active glycation in neurofibrillary pathology of Alzheimer disease: Ne{open}-(carboxymethyl)lysine and hexitol-lysine. Free Radic. Biol. Med. 2001, 31:175-180.
44. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 1994, 91:5710-5714.
45. Smith M.A., Sayre L.M., Vitek M.P., Monnier V.M., Perry G. Early AGEing and Alzheimer's. Nature 1995, 374:316.
46. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 2003, 23:8955-8966.
47. Höglinger G.U., Carrard G., Michel P.P., Medja F., Lombès A., Ruberg M., Friguet B., Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 2003, 86:1297-1307.